A group of authors critically evaluated and interpreted the evidence linking mitochondrial dysfunction and metabolic changes to the pathogenesis of Alzheimer’s disease (AD).
Ex-Metacrine chief Preston Klassen recharges at microRNA biotech; Allogene begins search for a CFO
→ Preston Klassen has mapped out his next destination as president and R&D chief of microRNA developer Regulus Therapeutics. Klassen was the CEO of Metacrine,